SynthesisInflammatory bowel diseases2026
Immunomodulators and Advanced Therapies for Induction of Remission in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Synthesis in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Adalimumab Therapy for Crohn's Disease and Axial Spondyloarthritis in Latent Tuberculosis:Sultan Qaboos University medical journal · 2026Pooled it
- Interventions for maintenance of surgically induced remission in Crohn's disease: a systematic review and network meta-analysis.BMJ open gastroenterology · 2025Pooled it
- Local and circulating cytotoxic CD4medRxiv : the preprint server for health sciences · 2026Article
- Limited willingness to switch from intravenous to subcutaneous treatment in paediatric inflammatory bowel disease.BMJ paediatrics open · 2026Article
- Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.Therapeutic advances in gastroenterology · 2026Article
- Network meta-analyses in IBD: pitfalls and promise for clinicians.Therapeutic advances in gastroenterology · 2026Review
- MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease.Insights into imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious reviews for Crohn's disease (CD) treatment have rarely considered advanced and immunomodulator medical therapies together. Our aim was to compare all therapies for efficacy and safety in induction of remission.
methodsWe searched databases up to June 2025. Our outcomes were clinical remission and response, endoscopic remission, and safety outcomes. We performed network meta-analyses and estimated risk ratios (RR) and 95% CIs. We used GRADE to assess certainty of results, and surface under the cumulative ranking curve for ranking treatments.
resultsA total of 79 RCTs with 20 724 participants were included. Interventions ranged from 2 to 30 weeks. There was moderate GRADE certainty of effectiveness over placebo for clinical remission for combination of adalimumab with thiopurines (RR, 2.87; 95% CI, 1.99-4.14; RD (Risk difference) = 35.3%; NNT (Number needed to treat) = 3, large magnitude), guselkumab (RR, 2.5; 95% CI, 1.95-3.21; RD = 28.4%; NNT = 4, moderate magnitude, adalimumab (RR, 2.46; 95% CI, 1.84-3.29; RD = 27.6% NNT = 4, moderate magnitude), combination of infliximab with thiopurines (RR, 2.43; 95% CI, 1.71-3.44; RD = 27%; NNT = 4, moderate magnitude), and ustekinumab (RR, 2.04; 95% CI, 1.69-2.46; RD = 19.6% NNT = 5, small magnitude). For endoscopic remission, there was moderate GRADE certainty of effectiveness for risankizumab (RR, 3.48; 95% CI, 2.18-5.58; RD = 17.4%, moderate magnitude). The certainty on safety varied, but treatments appear generally safe in the short term.
conclusionCombination of anti-tumor necrosis factors (anti-TNFs) and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have similar effect sizes but with increased imprecision of the estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.